HG202 is the first-ever clinical-stage CRISPR/Cas13 RNA-editing and the only clinical-stage RNA-targeting therapy for nAMD. “This open IND for HG202 by the US FDA – the first regulator to have cleared ...

The "RNA world" hypothesis proposes that the earliest life on Earth may have been based on RNA—a single-stranded molecule ...

Researchers discovered alcohol use disorder (AUD) and Alzheimer's disease (AD) exhibit similar patterns of gene dysregulation ...

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts ...

Recently IPO'ed biotech Camp4 Therapeutics (NASDAQ:CAMP) recorded its best intraday gains since its public debut in October as J.P. Morgan and Piper Sandler launched its coverage with Overweight ...

Could the controversial COVID drug hydroxychloroquine be repurposed as a promising medication for cancer? Researchers believe ...

Think back to that basic biology class you took in high school. You probably learned about organelles, those little "organs" ...

VIR's HDV and HBV treatments remain Vir's primary value drivers, with upcoming catalysts in Q4 2024 and 2025. Find out why ...

As a key player in protein synthesis, mRNA technology is transforming therapeutics, offering solutions for cancer, genetic disorders, and regenerative medicine.

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules ...

People with FSHD, ages 16 to 70, enrolled in this Phase 1/2 FORTITUDE trial cohort will aid biomarker data to support early approval request.

Membraneless organelles, also called biomolecular condensates, are changing how scientists think about protein chemistry, ...